Sartorius AG

Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding

Retrieved on: 
Tuesday, February 6, 2024
Financial services, Failure, Sartorius AG, Order, Person, European, Prospectus, European Economic Area, Council, Gross metropolitan product, Advertising, Risk, State, Sale, AMF, European Parliament, Equity carve-out, Finance, Security (finance)

This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.

Key Points: 
  • This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.
  • The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations.
  • The issuance by the Issuer or the subscription of the Shares may be subject to legal and regulatory restrictions in certain jurisdictions.
  • This announcement may not be published, forwarded or distributed, directly or indirectly, in South Africa, Australia, Canada or Japan.

EQS-News: Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028

Retrieved on: 
Tuesday, January 30, 2024
CO2, Patient, Deleveraging, Forecasting, Research, Sartorius, Face, Electricity, Novasep, Public expenditure, Acquisition, Sartorius AG, Acceleration, Transfection, Weakness, Vaccine, News, Growth

Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)

Key Points: 
  • Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • Sales revenue in the Americas region was down 14.9 percent and accounted for around 38 percent of the Group total.
  • In the Asia | Pacific region, in particular, the pronounced weakness of the market in China had a significant impact, with sales revenue down 22.1 percent.
  • Sartorius intends to continue its profitable growth path in the long term and expects to grow faster than the market.

Microcarriers Market Worth $3.3 Billion | MarketsandMarkets

Retrieved on: 
Wednesday, December 6, 2023
Sartorius AG, Cell biology, Thermo Fisher Scientific, Research, Organization, Investment, Market development, Stemcell Technologies, Regenerative medicine, Bioreactor, High, Tissue engineering, Danaher Corporation, Pulse, Growth, LATAM, Fujifilm, Filtration, Corning Inc., Merck Group, Getinge Group, MEA, Gesellschaft mit beschränkter Haftung, Fine chemical, Pharmaceutical industry, Video game, Marketing

Consumables accounted for the major market share of microcarriers market in 2022.

Key Points: 
  • Consumables accounted for the major market share of microcarriers market in 2022.
  • Additionally, the growing R&D activities in the biotechnology sector are promoting the growth of the microcarriers market.
  • Based on application, the microcarriers market has been segregated into biopharmaceutical production, tissue engineering and regenerative medicine, and other applications.
  • Microcarriers Market Size - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall microcarriers market and its subsegments.

Microcarriers Market Worth $3.3 Billion | MarketsandMarkets

Retrieved on: 
Wednesday, December 6, 2023
Sartorius AG, Cell biology, Thermo Fisher Scientific, Research, Organization, Investment, Market development, Stemcell Technologies, Regenerative medicine, Bioreactor, High, Tissue engineering, Danaher Corporation, Pulse, Growth, LATAM, Fujifilm, Filtration, Corning Inc., Merck Group, Getinge Group, MEA, Gesellschaft mit beschränkter Haftung, Fine chemical, Pharmaceutical industry, Video game, Marketing

Consumables accounted for the major market share of microcarriers market in 2022.

Key Points: 
  • Consumables accounted for the major market share of microcarriers market in 2022.
  • Additionally, the growing R&D activities in the biotechnology sector are promoting the growth of the microcarriers market.
  • Based on application, the microcarriers market has been segregated into biopharmaceutical production, tissue engineering and regenerative medicine, and other applications.
  • Microcarriers Market Size - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall microcarriers market and its subsegments.

Life Science Equipment Market to Achieve $92.21 Billion Valuation by 2030, Driven by Advancements in Genomics and Proteomics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 7, 2023
Genetics, Science, Health, Other Science, Shimadzu, Food safety, Sartorius AG, Biotechnology, Prevalence, Research, ChromeOS, PerkinElmer, Bruker, Growth, Genomics, Danaher Corporation, Dickinson, SE, Agilent Technologies, Proteomics, Waters Corporation, Automation, Fine chemical

The "Life Science Equipment Market by Technology, End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Life Science Equipment Market by Technology, End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global life science equipment market is on a growth trajectory and is expected to reach a valuation of $92.21 billion by 2030, with a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030.
  • Pharmaceutical and Biotechnology Dominance: Among end users, the pharmaceutical and biotechnology industry segment is estimated to account for the largest share of the life science equipment market in 2023.
  • Regional Insights: In 2023, North America is anticipated to hold the largest share of the life science equipment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech

Retrieved on: 
Thursday, October 26, 2023
Quotient, Public expenditure, EBITDA, Acquisition, CEST, Growth, Sartorius AG, Forecasting, Security (finance), Creative industries, Pharmaceutical industry, Retail, Arms industry, Cryptocurrency

Considering the strong fundamental growth drivers of our markets, we expect profitable growth in 2024 and beyond,” said René Fáber, CEO of Sartorius Stedim Biotech.

Key Points: 
  • Considering the strong fundamental growth drivers of our markets, we expect profitable growth in 2024 and beyond,” said René Fáber, CEO of Sartorius Stedim Biotech.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this release.
  • René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s business results with analysts and investors in a conference call at 12.30 p.m. CEST on October 19, 2023.

EQS-News: SARTORIUS AG: Sartorius nine-month figures: Normalization of demand continues after end of pandemic

Retrieved on: 
Thursday, October 26, 2023
Quotient, Sartorius AG, Federal Executive Boards, Vaccine, Public expenditure, EBITDA, Acquisition, CEST, Research, Sartorius, Novasep, CFO, ID Labs production discography, Forecasting, Security (finance), Pharmaceutical industry, Fine chemical, Cryptocurrency, Arms industry, Management

For the full year, Sartorius expects a decline in sales revenue by approximately 17 percent, with an underlying EBITDA margin of slightly above 28 percent.

Key Points: 
  • For the full year, Sartorius expects a decline in sales revenue by approximately 17 percent, with an underlying EBITDA margin of slightly above 28 percent.
  • “2023 will be a year of normalization for Sartorius as well as for the market as a whole.
  • The reduction of inventories by our customers after the end of the pandemic is taking longer than expected and is thus delaying the recovery.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023

Retrieved on: 
Tuesday, October 17, 2023
Quotient, MAR, EBITDA, Forecasting, COVID-19, Regulatory News Service, Sartorius AG, Pharmaceutical industry, Cryptocurrency

The preliminary underlying EBITDA declined as a result of the volume development and product mix effects to 594 million euros (PY: 912 million euros).

Key Points: 
  • The preliminary underlying EBITDA declined as a result of the volume development and product mix effects to 594 million euros (PY: 912 million euros).
  • Sartorius Stedim Biotech will publish the full set of the 9-month figures for 2023 as scheduled on October 19, 2023.
  • Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards.
  • Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.

Laboratory Proficiency Testing Market worth $1.6 billion | MarketsandMarkets

Retrieved on: 
Wednesday, October 4, 2023
Emerald, Public, Food safety, Chromatography, Lung compliance, Merck Group, AOAC, Incidence, Randox, Risk, Waters Corporation, Laboratory, University, College of American Pathologists, Food Animal Concerns Trust, Bio-Rad Laboratories, Culture, Mpox, Cosmetics, Research, Environmental monitoring, Growth, PCR, Microbiology, Safety, Government, American Industrial Hygiene Association, Dietary supplement, Fera Science, Water, Quality assurance, Spectrophotometry, Ortho Clinical Diagnostics, Partnership, College, Sartorius AG, Food quality, Education, Communities and Justice Directorates, SPEX, Medical device, Fine chemical, Airline

In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.

Key Points: 
  • In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.
  • In 2022, the cell culture segment held the largest market share in the Laboratory Proficiency Testing market.
  • The APAC Laboratory Proficiency Testing market is projected to grow at the highest rate during the forecast period.
  • The laboratory proficiency testing market is segmented into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Laboratory Proficiency Testing Market worth $1.6 billion | MarketsandMarkets

Retrieved on: 
Wednesday, October 4, 2023
Emerald, Public, Food safety, Chromatography, Lung compliance, Merck Group, AOAC, Incidence, Randox, Risk, Waters Corporation, Laboratory, University, College of American Pathologists, Food Animal Concerns Trust, Bio-Rad Laboratories, Culture, Mpox, Cosmetics, Research, Environmental monitoring, Growth, PCR, Microbiology, Safety, Government, American Industrial Hygiene Association, Dietary supplement, Fera Science, Water, Quality assurance, Spectrophotometry, Ortho Clinical Diagnostics, Partnership, College, Sartorius AG, Food quality, Education, Communities and Justice Directorates, SPEX, Medical device, Fine chemical, Airline

In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.

Key Points: 
  • In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.
  • In 2022, the cell culture segment held the largest market share in the Laboratory Proficiency Testing market.
  • The APAC Laboratory Proficiency Testing market is projected to grow at the highest rate during the forecast period.
  • The laboratory proficiency testing market is segmented into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.